Clean Slate: The Psychedelic Revolution in Healthcare with Maria Velkova

Maria Velkova, managing partner of Tabula Rasa Ventures, discusses the use of psychedelics in therapy and the work her organization is doing to support the space. She explains that psychedelic-assisted therapy is a novel care delivery model that combines traditional therapy with the use of psychedelic medicines. Velkova emphasizes the efficacy of these therapies, particularly for veterans who have high unmet needs. She also discusses the history of psychedelics and the negative connotations associated with them, as well as the current shift towards acceptance and understanding. The conversation explores the impact of psychedelics on the healthcare ecosystem and the potential for personalized, holistic, and disease-modifying approaches to mental health care. The conversation explores the role of money and investment in the psychedelic industry, the potential approval of MDMA-assisted therapy by the FDA, and the challenges and stigma surrounding psychedelic research and therapy. It emphasizes the need for capital to scale and provide broad patient access to innovative therapies. The conversation also discusses the upcoming FDA decision on MDMA-assisted therapy and the potential outcomes. The importance of real-world evidence and the evolving nature of science in understanding the benefits of psychedelics is highlighted. Resources for learning more about psychedelics are provided.
-Psychedelic-assisted therapy combines traditional therapy with the use of psychedelic medicines and has shown incredible efficacy, particularly for veterans with high unmet needs.
-There has been a historical negative connotation associated with psychedelics, but there is now a shift towards acceptance and understanding.
-Psychedelics have the potential to revolutionize the healthcare ecosystem by offering personalized, holistic, and disease-modifying approaches to mental health care.
-The psychedelic ecosystem is characterized by collaboration, intentionality, and a focus on bringing healing to as many patients as possible.
Investment in the psychedelic space faces challenges due to stigma and skepticism, but there is growing interest and belief in the potential of these therapies. Money and investment play a crucial role in scaling and providing broad patient access to innovative therapies in the psychedelic industry.
-The FDA is considering the approval of MDMA-assisted therapy for PTSD, with phase three clinical trials showing promising results.
-Challenges and stigma still exist in the psychedelic research and therapy space, but the growing evidence of efficacy is leading to a shift in perception.
-The FDA decision on MDMA-assisted therapy could result in approval, a request for more data, or a straight-up rejection.
-Real-world evidence and the evolving nature of science are important in understanding the benefits of psychedelics.
Resources such as peer-reviewed articles, podcasts, and platforms like Psychedelic Alpha, DoubleBlind, and Lucid News can provide valuable information on psychedelics.

Chapters
00:00 Introduction and Background
05:14 The Shift towards Acceptance of Psychedelics
10:39 The Potential of Psychedelics in Understanding the Brain
18:15 Revolutionizing Mental Health Care with Psychedelics
28:15 Challenges and Opportunities in the Psychedelic Space
33:54 The Potential Approval of MDMA-Assisted Therapy by the FDA
43:49 Challenges and Stigma in Psychedelic Research and Therapy
49:27 The FDA Decision on MDMA-Assisted Therapy: Possible Outcomes
51:12 The Importance of Real-World Evidence and the Evolving Nature of Science
53:06 Resources for Learning More about Psychedelics

Видео Clean Slate: The Psychedelic Revolution in Healthcare with Maria Velkova канала AGLX